These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 25889309)

  • 1. Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenib.
    Wong AL; Lim JS; Sinha A; Gopinathan A; Lim R; Tan CS; Soh T; Venkatesh S; Titin C; Sapari NS; Lee SC; Yong WP; Tan DS; Pang B; Wang TT; Zee YK; Soong R; Trnkova Z; Lathia C; Thiery JP; Wilhelm S; Jeffers M; Goh BC
    J Transl Med; 2015 Feb; 13():57. PubMed ID: 25889309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
    Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
    Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Tolerability and efficacy of regorafenib in patients with unresectable metastatic colorectal cancer].
    Tanaka A; Sadahiro S; Suzuki T; Okada K; Saito G
    Gan To Kagaku Ryoho; 2014 Oct; 41(10):1231-6. PubMed ID: 25335705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and molecular assessment of regorafenib monotherapy.
    Kakizawa N; Suzuki K; Fukui T; Takayama Y; Ichida K; Muto Y; Hasegawa F; Watanabe F; Kikugawa R; Tsujinaka S; Futsuhara K; Miyakura Y; Noda H; Rikiyama T
    Oncol Rep; 2017 Apr; 37(4):2506-2512. PubMed ID: 28259999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum CA19-9 Response Is an Early Predictive Marker of Efficacy of Regorafenib in Refractory Metastatic Colorectal Cancer.
    Komori A; Taniguchi H; Hamauchi S; Masuishi T; Kito Y; Narita Y; Tsushima T; Ishihara M; Todaka A; Tanaka T; Yokota T; Kadowaki S; Machida N; Ura T; Fukutomi A; Ando M; Onozawa Y; Tajika M; Yasui H; Muro K; Mori K; Yamazaki K
    Oncology; 2017; 93(5):329-335. PubMed ID: 28866662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II study.
    Khan K; Rata M; Cunningham D; Koh DM; Tunariu N; Hahne JC; Vlachogiannis G; Hedayat S; Marchetti S; Lampis A; Damavandi MD; Lote H; Rana I; Williams A; Eccles SA; Fontana E; Collins D; Eltahir Z; Rao S; Watkins D; Starling N; Thomas J; Kalaitzaki E; Fotiadis N; Begum R; Bali M; Rugge M; Temple E; Fassan M; Chau I; Braconi C; Valeri N
    Gut; 2018 Aug; 67(8):1484-1492. PubMed ID: 28790159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Total lesion glycolysis (TLG) as an imaging biomarker in metastatic colorectal cancer patients treated with regorafenib.
    Lim Y; Bang JI; Han SW; Paeng JC; Lee KH; Kim JH; Kang GH; Jeong SY; Park KJ; Kim TY
    Eur J Nucl Med Mol Imaging; 2017 May; 44(5):757-764. PubMed ID: 27888325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial.
    Argilés G; Saunders MP; Rivera F; Sobrero A; Benson A; Guillén Ponce C; Cascinu S; Van Cutsem E; Macpherson IR; Strumberg D; Köhne CH; Zalcberg J; Wagner A; Luigi Garosi V; Grunert J; Tabernero J; Ciardiello F
    Eur J Cancer; 2015 May; 51(8):942-9. PubMed ID: 25818084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring levels of circulating cell-free DNA in patients with metastatic colorectal cancer as a potential biomarker of responses to regorafenib treatment.
    Pastor B; André T; Henriques J; Trouilloud I; Tournigand C; Jary M; Mazard T; Louvet C; Azan S; Bauer A; Roch B; Sanchez C; Vernerey D; Thierry AR; Adenis A
    Mol Oncol; 2021 Sep; 15(9):2401-2411. PubMed ID: 33934494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors.
    Crona DJ; Keisler MD; Walko CM
    Ann Pharmacother; 2013 Dec; 47(12):1685-96. PubMed ID: 24259629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer.
    Suenaga M; Mashima T; Kawata N; Wakatsuki T; Horiike Y; Matsusaka S; Dan S; Shinozaki E; Seimiya H; Mizunuma N; Yamaguchi K; Yamaguchi T
    Oncotarget; 2016 Jun; 7(23):34811-23. PubMed ID: 27166185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program.
    Adenis A; de la Fouchardiere C; Paule B; Burtin P; Tougeron D; Wallet J; Dourthe LM; Etienne PL; Mineur L; Clisant S; Phelip JM; Kramar A; Andre T
    BMC Cancer; 2016 Jul; 16():412. PubMed ID: 27389564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD).
    Carrato A; Benavides M; Massutí B; Ferreiro-Monteagudo R; García Alfonso P; Falcó E; Reboredo M; Cano T; Gallego J; Viéitez JM; Layos L; Salud A; Polo E; Dotor E; Durán-Ogalla G; Rodriguez-Garrote M; Calvo A; Grande E; Aranda E
    BMC Cancer; 2019 Jun; 19(1):533. PubMed ID: 31159765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regorafenib-Induced Hypothyroidism as a Predictive Marker for Improved Survival in Metastatic or Unresectable Colorectal Cancer Refractory to Standard Therapies: A Prospective Single-Center Study.
    Kim JH; Kim SY; Kim KP; Kim TW; Chae SY; Kim HJ; Kim JS; Ryu JS; Moon DH; Kim JE; Hong YS
    Target Oncol; 2019 Dec; 14(6):689-697. PubMed ID: 31555963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-L1 Expression on Circulating Tumour Cells May Be Predictive of Response to Regorafenib in Patients Diagnosed with Chemorefractory Metastatic Colorectal Cancer.
    Raimondi L; Raimondi FM; Di Benedetto L; Cimino G; Spinelli GP
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32962309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regorafenib therapy in metastatic colorectal cancer patients: markers and outcome in an actual clinical setting.
    Unseld M; Filip M; Seirl S; Gleiss A; Bianconi D; Kieler M; Demyanets S; Scheithauer W; Zielinski C; Prager G
    Neoplasma; 2018; 65(4):599-603. PubMed ID: 29940763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced dose of salvage-line regorafenib monotherapy for metastatic colorectal cancer in Japan.
    Hirano G; Makiyama A; Makiyama C; Esaki T; Oda H; Uchino K; Komoda M; Tanaka R; Matsushita Y; Mitsugi K; Shibata Y; Kumagai H; Arita S; Ariyama H; Kusaba H; Akashi K; Baba E
    Anticancer Res; 2015 Jan; 35(1):371-7. PubMed ID: 25550574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of regorafenib in the treatment of metastatic colorectal cancer: A systematic review.
    Røed Skårderud M; Polk A; Kjeldgaard Vistisen K; Larsen FO; Nielsen DL
    Cancer Treat Rev; 2018 Jan; 62():61-73. PubMed ID: 29175677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A higher ctDNA fraction decreases survival in regorafenib-treated metastatic colorectal cancer patients. Results from the regorafenib's liquid biopsy translational biomarker phase II pilot study.
    Unseld M; Belic J; Pierer K; Zhou Q; Moser T; Bauer R; Piringer G; Gerger A; Siebenhüner A; Speicher M; Heitzer E; Prager GW
    Int J Cancer; 2021 Mar; 148(6):1452-1461. PubMed ID: 32949150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigation of Regorafenib-induced Hypothyroidism in Patients with Metastatic Colorectal Cancer.
    Sugita K; Kawakami K; Yokokawa T; Mae Y; Toya W; Hagino A; Suzuki K; Suenaga M; Mizunuma N; Yamaguchi T; Hama T
    Anticancer Res; 2015 Jul; 35(7):4059-62. PubMed ID: 26124355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.